Cohort information

CONGO				WP2
Organization		Fondation Congolaise pour la recherche médicale (FCRM)
Name of cohort		Retrospective cross-sectional study on SARS-CoV-2 variant analysis
Referring partner		FCRM
Cohort Information	Country(-ies), cities, regions or centers involved	Republic of Congo, Brazzaville, FCRM
	Time of data collection	03/2020	03/2023
	Enrolment	Inactive
	Study setting	Multi-centers
Population	Age	Adults,Elderly
	Type	Both
	Total number of patients	76
	Site of enrolment (WP2)	Outpatient
Data collection	Clinical data	True
	Serological data	True
	Genetic data	True
	Sample collection	True
	Sample collected	Whole blood	No
		PBMC	No
		Dry-spot blood	No
		Plasma	Yes
		Serum	No
		Stool	No
		NP swabs	No
		Other	None
Description	The main objective of this project is to assess in people living in Brazzaville who have been vaccinated with Sinopharm 2, Sputnik V or Johnson & Johnson vaccines, the protection provided by these three vaccines; the specific objectives are: - Evaluate the immune response, in particular the humoral response induced by the 3 vaccines, by determining the level and type of antibodies in people vaccinated over 12 months; - Evaluate the number of infections and re-infections in people vaccinated over 12 months - Determine the most suitable vaccine for the study population by comparing the protection indicators according to the vaccine administered The participants in this project are volunteers living in Brazzaville vaccinated and having received the first dose of one of the three (3) vaccines currently used in Congo. They will be included in CCLAM where they will receive essential information, will be registered and will offer a nasopharyngeal swab for RT-PCR screening for sars-cov2, and a blood sample for antibody testing against this virus. These participants will be followed for a period of one year at the rate of four visits: D1 after the first dose and then 14 days, 2 months, 6 months and 12 months after the 2nd dose of vaccines.
Publications	- Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in Congolese individuals [BMC Infectious Diseases] - Mucosal response of inactivated and recombinant COVID-19 vaccines in Congolese individuals [Immunity, Inflammation and Disease]